Portage Biotech (NASDAQ:ALP) Raised to Hold at Zacks Research

Portage Biotech (NASDAQ:ALP) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright began coverage on shares of Portage Biotech in a research report on Monday. They issued a “neutral” rating and a $0.25 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Portage Biotech has a consensus rating of “Reduce” and a consensus price target of $0.25.

Portage Biotech Stock Down 7.1%

Shares of ALP stock opened at $0.15 on Tuesday. Portage Biotech has a 1 year low of $0.14 and a 1 year high of $13.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31. The business’s fifty day moving average is $0.28 and its 200-day moving average is $0.34. The stock has a market cap of $3.54 million, a PE ratio of -0.02 and a beta of 0.61.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings data on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The firm had revenue of $0.05 million during the quarter. Equities analysts expect that Portage Biotech will post -0.28 earnings per share for the current fiscal year.

Trending Headlines about Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright assigned Portage Biotech a $0.25 price target, above the current price of approximately $0.15, implying potential upside if the company’s clinical and financial outlook improves. However, the firm’s rating remains Neutral. HC Wainwright Initiates Coverage on Portage Biotech
• Neutral Sentiment: Zacks Research upgraded Portage Biotech to a Hold rating. The change removes a more negative stance but does not represent a buy recommendation, likely limiting the immediate positive effect on ALP shares. Zacks Research Portage Biotech Rating
• Neutral Sentiment: HC Wainwright’s recent coverage reiterates a Neutral rating and a $0.25 target, providing a valuation reference but little evidence of a near-term catalyst. HC Wainwright Weighs in on Portage Biotech Q1 Earnings
• Negative Sentiment: HC Wainwright forecasts continued quarterly losses for fiscal 2027, including EPS of negative $0.10 in Q1 and negative $0.07 in Q2 and Q3, with a full-year loss of approximately $0.28 per share. The estimates reinforce concerns about Portage Biotech’s limited revenue base and need for additional funding.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.